BOSTON -- The Biotech Mailbag marches on, even with a Thanksgiving turkey hangover.
This week: Pipex Pharmaceuticals(PP Quote) Hythiam(HYTM Quote) Amgen(AMGN Quote) Isis Pharmaceuticals(ISIS Quote).Anand J. writes to ask about Pipex Pharmaceuticals: "Any thoughts on this company with several late-stage drugs? Their lead drug Coprexa is very close to an [FDA] filing. Also, management holds a lot of the company stock and runs a tight ship, which is always a good sign." Regular readers know that I place a lot of emphasis (perhaps too much) on the quality and trustworthiness of management. This is especially important in small-cap, thinly traded biotech stocks like Pipex. Steve Kanzer runs Pipex and is the largest shareholder, owning just under half the company. This is a photo montage from Time that includes a shot of Kanzer taken last May during an FDA advisory panel meeting convened to discuss a drug from Dor BioPharma(DORB Quote), where Kanzer was vice chairman at the time. He has since resigned from Dor's board. Scroll to photo No. 4 to see Kanzer being physically restrained and forcibly removed from the meeting. Perhaps he had too much coffee that day. I hope so, but I have my doubts. Suffice to say, he's not exactly high-quality biotech management material in my book. Kanzer factored into another old story of mine on Dor, which also makes me feel uneasy about his leadership.
- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |














